Reference : Community- and mHealth-based integrated management of diabetes in primary healthcare ... |
Scientific congresses, symposiums and conference proceedings : Unpublished conference | |||
Human health sciences : Endocrinology, metabolism & nutrition Human health sciences : General & internal medicine Human health sciences : Public health, health care sciences & services Human health sciences : Multidisciplinary, general & others | |||
http://hdl.handle.net/10993/32740 | |||
Community- and mHealth-based integrated management of diabetes in primary healthcare in Rwanda (D²Rwanda): The study protocol | |
English | |
Uwizihiwe, Jean Paul ![]() | |
Lygidakis, Charilaos ![]() | |
Vögele, Claus ![]() | |
Condo, Jeanine [] | |
D'Ambrosio, Conchita ![]() | |
Kallestrup, Per ![]() | |
29-Jun-2017 | |
Yes | |
International | |
22nd WONCA Europe Conference | |
from 28-06-2017 to 01-07-2017 | |
WONCA Europe | |
Prague | |
Czech Republic | |
[en] mHealth ; eHealth ; global health ; primary care ; diabetes | |
[en] Introduction: The diabetes mellitus (DM) prevalence in Rwanda is estimated at 3.5%. In 2013, there were only one medical doctor and one nurse per 15,000 and 1,200 people respectively in Rwanda. A new programme employing frontline workers (Home-Based Community Practitioners (HBCPs)) is currently piloted, aiming at following-up patients with non-communicable diseases in their communities.
We hypothesise that the management of DM at community level will improve following the introduction of a HBCP programme with regular monthly assessments and disease management, coupled with integration of a mobile health (mHealth) application with patient diaries, notifications and educational material. Objective: The aim of the study is to determine the efficacy of such an integrated programme in Rwanda. Methods: The study is designed as a one-year, open-label cluster trial of two interventions (arm1: HBCP programme, arm2: HBCP programme + mHealth application) and usual care (control). The primary outcomes will be changes in glycated haemoglobin levels and health-related quality of life. Mortality, complications, health literacy, mental well-being and treatment adherence will be assessed as secondary outcomes. Measurements will be conducted at baseline, 6 and 12 months. An intention-to-treat approach will be used to evaluate outcomes. Before trial onset, ethical approval will be sought in Rwanda, Luxembourg and Denmark, and a cross-cultural adaptation of questionnaires and a pilot will be carried out. Relevance: The project will provide evidence on the efficacy of innovative approaches for integrated management of DM and may spur the development of similar solutions for other chronic diseases in low-resource settings. | |
Karen Elise Jensens Fond, Aarhus University, University of Luxembourg | |
The D²Rwanda Study | |
Researchers ; Professionals | |
http://hdl.handle.net/10993/32740 |
There is no file associated with this reference.
All documents in ORBilu are protected by a user license.